NEW YORK, Dec 6 - Genome Therapeutics said Wednesday that Bristol-Myers Squibb had renewed its license for the PathoGenome database, extending a subscription that began in 1997.
Under the terms of the agreement, Bristol-Myers Squibb will continue to have non-exclusive access to the database and will pay annual subscription fees as well as milestone payments and royalties on any small molecules developed as a result of the collaboration. Genome Therapeutics retains rights associated with the therapeutic and vaccine use of bacterial genes or gene products derived from the database.
No other terms were disclosed.
" Through mining the PathoGenome Database, we have been able to dramatically expand the number of potential drug targets in our anti-infectives pipeline," John Barrett, executive director of infectious diseases research at Bristol-Myers Squibb, said in a statement.
Genome Therapeutics considers new anti-infectives to be leading candidates for the first commercial products based on genomic data.
The PathoGenome database offers functionally annotated sequence information on over 30 microbial pathogens, including Staphylococcus , Pseudomonas , Streptococcus , Enterococcus , Acinetobacter , Aspergillus , Bacteroides , Enterobacter , Klebsiella , and Candida species.
Originally available only by subscription, the database has been available since August on a pay-per-use basis through Compugen’s search engine LabOnWeb.com. The fee is based on the amount of information accessed per search.
Other subscribers to the database include Aventis, Bayer, bioMerieux, and Schering-Plough.